New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. (Q47878245)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 September 2008

Language	Label	Description	Also known as
English	New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.	scientific article published on 18 September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Plasmodium vivax

0 references

0 references

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

Salmonella Typhimurium

1 reference

based on heuristic

inferred from title

Daniel Youssef Bargieri

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Daniela Santoro Rosa

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Luis Carlos de Souza Ferreira

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Catarina J M Braga

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Bruna O Carvalho

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Fabio T M Costa

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Noeli Maria Espíndola

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Adelaide José Vaz

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Irene S Soares

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Mauricio M Rodrigues

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

0 references

publication date

18 September 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6132-6142

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18804504%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Vivax malaria: neglected and not benign

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Chloroquine resistance in Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Neglect of Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

An update on the search for a Plasmodium vivax vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Targeting the Plasmodium vivax Duffy-binding protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Innate immune recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Pathogen recognition and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

The attenuated phenotype of a Salmonella typhimurium flgM mutant is related to expression of FliC flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Protective immunity to malaria: studies with cloned lines of Plasmodium chabaudi chabaudi in CBA/Ca mice. III. Protective and suppressive responses induced by immunization with purified antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Identification of a novel negative role of flagellin in regulating IL-10 production.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

based on heuristic

inferred from DOI database lookup

Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

based on heuristic

inferred from DOI database lookup

Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.070

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47878245&oldid=1796188338"